Aravive — Investor Presentation (November 2021)
46 slides from Aravive's investor presentation, Nov 12, 2021
Slide 1: Developing Transformative Targeted Cancer Therapeutics
¢°9 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation November 2021 ARAV (NASDAQ)
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that may discuss Aravive's plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- looking statements generally include statements tha
Slide 3: Developing Transformative Targeted Cancer Therapeutics
Developing Transformative Targeted Cancer Therapeutics Batiraxcept (AVB-500): Differentiated Approach to Targeted Inhibition of GAS6/AXL Signaling Pathway Multiple Upcoming Clinical Milestones Registrational Phase 3 Trial in Platinum-Resistant Ovarian Cancer (PROC) Ongoing Phase 1b trial demonstrate
Slide 4: Experienced Management and Board of Directors
Experienced Management and Board of Directors SENIOR MANAGEMENT 2 eg a ‘ Gail Mcintyre, Ph.D., DABT Reshma Rangwala, M.D., Ph.D. Vinay Shah BOARD OF DIRECTORS Chairman of the Board Director Director Director Director Director Director Director FredEshelman, Amato Giaccia,Ph.D. Peter Ho, M.D., John H
Slide 5: Aravive Pipeline
Aravive Pipeline Opportunity for Expansion into Additional Indications and Drug Combinations Indication Batiraxcept (AVB-500) OVARIAN CANCER Platinum Resistant (batiraxcept + paclitaxel) CLEAR CELL RENAL CANCER + 1 Line (batiraxcept + cabozantinib + nivolumab) + 2°8* Line (batiraxcept + cabozantinib
Slide 6: Urgent Unmet Needs & Large Market Opportunities
Urgent Unmet Needs & Large Market Opportunities ~106K Addressable Patients & Potential to Expand into Other Cancers and Earlier Lines of Therapy @ PROC 5th leading cause of cancer deaths among women in U.S. ~70% of patients diagnosed with advanced-stage disease ADDRESSABLE PATIENTS U.S. ~12,000 EU ~
Slide 7: Upcoming Key Milestones
Upcoming Key Milestones Completion of Enrollment in Phase 1b Pancreatic Adenocarcinoma Trial Preliminary Phase 1b Pancreatic Adenocarcinoma Initiation of Phase 2 Trial Data Pancreatic Adenocarcinoma Trial Updated Phase 1b & Preliminary Updated Phase 1b & Preliminary Phase Phase 2 Part AccRCC Trial D
Slide 8: GAS6/AXL Signaling Pathway
GAS6/AXL Signaling Pathway Drives Activation, Migration and Invasion of Abnormal Cells Inhibiting GAS6 Preclinically + Anti-tumor activity in many tumor models, including ovarian, kidney, pancreatic, and breast Blocks tumor invasion & metastasis Overcomes acquired drug resistance + Ameliorates desmo
Slide 9: Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhibitor
Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhibitor Modified AXL-Fc fusion protein engineered for strong stability and very high affinity for GAS6 + ~200 fold greater affinity for human GAS6 compared to native AXL receptor * Preclinical data demonstrated relationship between aff
Slide 10: Batiraxcept (AVB-500) Inhibits Metastasis and Tumor Growth
Batiraxcept (AVB-500) Inhibits Metastasis and Tumor Growth GAS is the sole activating ligand of AXL ©2021 Aravive, Inc. Batiraxcept binds GAS6, preventing it from binding and activating AXL 10
Slide 11: Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
w Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
Slide 12: Platinum-Resistant Ovarian Cancer Current Treatment Landscape
Platinum-Resistant Ovarian Cancer Current Treatment Landscape Per current NCCN Clinical Practice Guidelines Clinical activity of paclitaxel in PROC’ in Oncology, Version 1.2020, for Ovarian Cancer = 13-22% ORR (Geet, aie + 2.8-4.4 months PES « For platinum-resistant disease, non-platinum-based * 10.
Slide 13: Summary of Phase 1a Healthy Volunteer and 1b PROC Studies
Summary of Phase 1a Healthy Volunteer and 1b PROC Studies Phase 1a single ascending dose and repeat dose study in healthy volunteers * 43 subjects participated; 42 dosed * Batiraxcept was well-tolerated across doses of 1-10 mg/kg Batiraxcept; no SAEs + No anti-drug antibodies (ADA) * 10 mg/kg (IV) a
Slide 14: Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure
Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure Modeling Identified RP2D of 15 mg/kg + Traditional MTD or DLT approach for identification of RP2D not appropriate for batiraxcept due to its benign safety profile + Exposure-response relationship identified by unsupervised computer
Slide 15: Batiraxcept + Paclitaxel Clinical Activity in Bevacizumab Subgroups
Batiraxcept + Paclitaxel Clinical Activity in Bevacizumab Subgroups * Clinical activity higher in patients who had not received Efficacy Data for Patients Receiving 10 mg/kg bevacizumab prior to entering study and 15 mg/kg of Batiraxcept & Paclitaxel — Phenomenon observed in other studies" Bevacizum
Slide 16: Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients
Subject 1D Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15 mg/kg groups) 96% were on 3+ Line of Therapy; Literature Demonstrates 85% of Patients on their 3° Line of Therapy have Progressive Disease by their First CT Scan’ PFS Months for Per-Protocol 10 mg/kg
Slide 17: Promising Responses in Patients in Later Lines of Therapy
Promising Responses in Patients in Later Lines of Therapy and <3 Month Platinum-Free Interval Compared to Literature CLINICAL RESPONSE CLINICAL RESPONSE OF BATIRAXCEPT+ OF CHEMOTHERAPY °% CHEMO’IN PATIENTS co, IN PATIENTS WITH 70% WITH <3MO 50% <3MO PLATINUM os PLATINUM FREE ee FREE INTERVAL~ 40% IN
Slide 18: Potentially More Favorable Benefit/Risk Profile
Potentially More Favorable Benefit/Risk Profile Compelling Anti-tumor Activity * ORR of 50% with 2 CRs, mPFS of 7.5 months, and mOS of 19 months in 10 & 15 mg/kg batiraxcept + PAC patients when trough levels exceeded MEC + ORR of 37% in 10 and 15 mg/kg batiraxcept + PAC patients, regardless of wheth
Slide 19: Batiraxcept Phase 3 Adaptive Registration Trial Design in PROC
Batiraxcept Phase 3 Adaptive Registration Trial Design in PROC (ClinicalTrials.gov NCT04729608) + FDA Feedback: If data positive, trial would support full approval in PROC; no further preclinical or clinical studies required for BLA at this time + Dosing: Batiraxcept every 2 weeks plus paclitaxel fo
Slide 20: Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Slide 21: ccRCC Current Treatment Landscape
ccRCC Current Treatment Landscape Limited treatment options for patients who have failed 1L Cabozantinib is the predominant drug used in 2L+ ccRCC' Clinical Activity: — Confirmed objective response rate for (60mg) cabozantinib alone ranges from 17%-28% Safety from METEOR trial2: — Dose reductions re
Slide 22: Strong Biological Rationale for Batiraxcept in ccRCC
Strong Biological Rationale for Batiraxcept in ccRCC A B GAS6/AXL in ccRCC" 120 srumor, 4 ae : : 5 ; lormal i | * AXL plays significant role in ccRCC invasion & metastasis = rig = g 80 1 + » AXL highly expressed in aggressive ccRCC tumors and s : gro) associated with poor outcome 5 ao g,| it fra we
Slide 23: Batiraxcept Effectively Targets Metastasis Preclinically in ccRCC
Batiraxcept Effectively Targets Metastasis Preclinically in ccRCC Direct regulation of GAS6/AXL signaling by HIF Promotes Renal Metastasis through SRC and MET * Stress conditions in cell activate GAS6/AXL signaling to allow cell to survive + Hypoxia (stress factor), typical in solid tumors, induces
Slide 24: Batiraxcept + Cabozantinib Phase 1b Trial Design in ccRCC
Batiraxcept + Cabozantinib Phase 1b Trial Design in ccRCC Phase 1b Trial of Batiraxcept in Combination with Cabozantinib Population: + 25 patients + Histologically confirmed metastatic ccRCC and patient has progressed on/after one front-line treatment regimen + Patients who previously had cabozantin
Slide 25: Baseline Demographic Data: All Patients Received a Prior Checkpoint Inhibitor
Baseline Demographic Data: All Patients Received a Prior Checkpoint Inhibitor; 61% Received a Prior VEGF TKI Data cutoff: November 9, 2021 17/18 patients ongoing treatment Demographics 15 mg/kg Batiraxcept and 20 mg/kg Batiraxcept and Cabozantinib, N=15 Cabozantinib, N=3 Gender (M, F) 12 (80%), 3 (2
Slide 26: Safety Profile of Batiraxcept and Cabozantinib is Manageable
Safety Profile of Batiraxcept and Cabozantinib is Manageable 15 mg/kg Batiraxcept + 20 mg/kg Batiraxcept + Safety Cabozantinib Cabozantinib N=15 N=3 Treatment Related Deaths ie) ie) Grade 3 Adverse Events (AEs), related to 2 (13%): HTN and 1 (33%): Thromboembolic Batiraxcept and Cabozantinib * Throm
Slide 27: Positive Initial Anti-Tumor Activity from Phase 1b Trial in ccRCC
Positive Initial Anti-Tumor Activity from Phase 1b Trial in ccRCC 44% (7/16) Best Objective Response Rate; No Patients Progressed at 15t Scan 15 mg/kg 20 mg/kg Efficacy Evaluable Total Batiraxcept + Batiraxcept + Cabozantinib Cabozantinib Best Objective Response Rate (Confirmed + Unconfirmed) WE Wei
Slide 28: Depth and Duration of Response in ccRCC
Depth and Duration of Response in ccRCC Batiraxcept + Cabozantinib Change from Baseline, (%) ; ° 2 4 6 8 10 12 14 «16 «18 «620 22 24 «26 «628 «6300 328486 Weeks on Study Patient 1D 102-001 gy 102-002 gy 103-001 gy 105-002 gy 105-003 gy 105-004 gy 106-001 gy 107-002 © 107-004 gq 107-005 fq 107-006 G
Slide 29: Patient 105-006 Baseline and Week 8 Scans
Baseline Week 8 Patient 105-006 had 4 target lesions at baseline measuring 25.6 cm in total. The images above depict two of these lesions (red arrows). The images on the left were obtained at baseline. The images on the right were obtained at Week 8. At week 8, 3 of the 4 target lesions, measuring a
Slide 30: Phase 1b/2 Trial Redesigned to Accelerate Development in ccRCC
Phase 1b/2 Trial Redesigned to Accelerate Development in ccRCC Strong Rationale to Evaluate Batiraxcept Monotherapy and Combination with Nivolumab + Cabozantinib in 1L Phase 1band Phase 2PartA: Phase 1b, N=15 Phase 2 Expansion, N=25 fa ee : => 2L+ccRCC: batiraxcept + cabozantinib Phase 1b: Phase 1b,
Slide 31: Batiraxcept: Pancreatic Adenocarcinoma
Batiraxcept: Pancreatic Adenocarcinoma
Slide 32: Pancreatic Adenocarcinoma Current Treatment Landscape
Pancreatic Adenocarcinoma Current Treatment Landscape Gemcitabine + nab-paclitaxel used in 1L treatment for advanced pancreatic adenocarcinoma Clinical Activity’: + ORR 23% with 1 patient with CR (<1%) + mPFS 5.5 months * mOS 8.5 months Safety’: * 33% of patients had dose reductions, resulting in a
Slide 33: Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b Trial Design
Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in 1L Pancreatic Adenocarcinoma Phase 1b Ongoing Phase 1b Trial Population: Timing: + Patients (N~20) with advanced or + First patient dosed in Phase metastatic pancreatic 1b portion of trial in August Batiraxcept adenocarcinoma elig
Slide 34: Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 2 Trial Design
Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in 1L Pancreatic Adenocarcinoma Planned Controlled, Randomized Phase 2 Trial Population: + Patients (N~60) with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemcitabine + nab-paclitaxel as first-line treatment
Slide 35: Corporate Highlights
Corporate Highlights
Slide 36: Financial Summary
Financial Summary $67.5 Million 20.9 Million No Debt Cash Runway Cash and Cash Shares Expected to Fund Equivalents Outstanding Base Operating Plan into 2H 2022 “Data as of 9/30/2021 ©2021 Aravive, Inc. 3 5
Slide 37: Developing Transformative Targeted Cancer Therapeutics
Developing Transformative Targeted Cancer Therapeutics Batiraxcept (AVB-500): Differentiated Approach to Targeted Inhibition of GAS6/AXL Signaling Pathway Multiple Upcoming Clinical Milestones Registrational Phase 3 Trial in Platinum-Resistant Ovarian Cancer (PROC) Ongoing Phase 1b trial demonstrate
Slide 38: Appendix
Slide 39: GAS6/AXL Role in Cancer
GAS6/AXL Role in Cancer Strong Biology, Challenging Target anes References * Technology discovered by Aravive’s scientific Up-Regulation founder at Stanford eeene pico Rankin etal., 2010 + Increased GAS6/AXL expression and signaling seen in Sun etal., 2004 many cancers and correlated with a poor pro
Slide 40: Strong Biological Rationale for Batiraxcept in PROC
AXL expressed in 0% (0 of 10) of normal ovarian tissue" AXL expressed in 73% (219 of 297) of all ovarian tumor samples, demonstrating that AXL expression is significantly higher (P < 0.0001) in ovarian carcinomas than normal ovarian epithelium? Batiraxcept single-agent activity in PROC and OC precli
Slide 41: Strong Biological Rationale for Batiraxcept in Pancreatic Adenocarcinoma
Strong Biological Rationale for Batiraxcept in Pancreatic Adenocarcinoma Preclinical data demonstrated increased survival in combination with gemcitabine, decreased fibrosis, and decreased tumor weight in orthotopic models Batiraxcept in combination with paclitaxel demonstrated compelling clinical a
Slide 42: Strong Patent Protection
Strong Patent Protection Stanford Licensed IP 1 Patent Family — Expiration 2031 US.: 3 Issued Patents Worldwide: 10 Issued (2 HK Recorded) Patents (EP Validated In 18 EP Countries) 3 Pending Patent Applications Stanford-Batiraxcept Co-owned IP 3 Patent Families — Expirations 2032 / 2033 / 2035 WSs 3
Slide 43: Clinical Activity of Cabozantinib in 2L+ ccRCC
Clinical Activity of Cabozantinib in 2L+ ccRCC Clinical Activity Objective Response % (95% Cl) Complete Response (%) Stable Disease (%) Progressive Disease (%) mPFS (months) (95% Cl) Safety Deaths (#) Grade >=3 Treatment Related AEs in More Than 10% of Patients (%) Treatment Discontinuations Due to
Slide 44: Rates and Depth of Response Associated with Overall Survival in ccRCC
Rates and Depth of Response Associated with Overall Survival in ccRCC + Retrospective studies have shown that early tumor shrinkage (eTS) based on target lesion reduction from baseline to first post-baseline scan, has predictive value for targeted therapies in RCC (Grunwald 2015; Grunwald 2016) + In
Slide 45: Strategic Collaborations
Strategic Collaborations 3DMecd Exclusive license agreement for development & commer ization of batiraxcept across all oncology indications in Greater China + $12M upfront payment received * $207M total potential development and commercial milestone payments; $9M development milestones achieved to d
Slide 46: Aravive
¢°9 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation November 2021 ARAV (NASDAQ)